Growth Hormone and Endothelial Function in Children
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00373386|
Recruitment Status : Completed
First Posted : September 8, 2006
Results First Posted : May 30, 2018
Last Update Posted : May 30, 2018
Objective: This study is designed to determine whether growth hormone treatment in children 8 to 18 years of age alters function of the lining of the arteries. This may play a role in increasing or decreasing the risk of heart disease.
Methods. Twenty children, for whom growth hormone therapy will be otherwise provided, will be studied before and 3 months after starting growth hormone. Subjects can be on other hormonal replacements but no other medications.
Each study will be done in the fasting state. The blood vessel function will be determined by measuring the change in forearm blood flow before and after blocking flow to the arm for 5 minutes. Blood will be drawn after the test to measure glucose, insulin and fats.
|Condition or disease||Intervention/treatment||Phase|
|Growth Hormone Deficiency Panhypopituitarism Short Stature||Drug: growth hormone||Phase 4|
The purpose of the research is to learn more about how the lining of arteries in the body (called the endothelium) is affected by growth hormone treatment in children and adolescents. Poor function by the blood vessels is associated with increased risk of heart disease or stroke. This research is being done because growth hormone treatment has been shown to make the endothelium work better in adults. Growth hormone treatment may have the same or different effects in children because the dose is larger in children.
Children between 8 and 18 years who are to be started on growth hormone will be eligible to participate. Blood vessel function will be studied before starting growth hormone and 3 months after. This will be done by measuring blood flow to the arm before and after 5 min of stopping blood flow to the arm. The three months of growth hormone will be given free.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||9 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Growth Hormone and Endothelial Function in Children|
|Study Start Date :||January 2005|
|Actual Primary Completion Date :||June 2007|
|Actual Study Completion Date :||December 2007|
Experimental: Growth Hormone
Growth hormone treatment 0.3 mg/kg/min
Drug: growth hormone
Growth Hormone treatment
- Reactive Hyperemic Response After 3 Months of Growth Hormone [ Time Frame: 3 months ]Forearm blood flow (FBF) was measured using strain gauge venous occlusion plethysmography using a Hokanson EC6 plethysmograph (DE Hokanson Inc, Bellevue, WA) in the left arm. With this technique sphygmomanometric cuffs were placed on the arm at the wrist and on the upper arm. During measurement the wrist cuff was inflated to 200 mmHg to occlude flow to the hand which is primarily skin blood flow and the upper arm cuff is inflated to 40 mmHG for 10 out of every 15 second to occlude venous return. FBF was obtained by measuring arm expansion with an indium-in-silastic strain gauge. Data was recorded using PowerLab and Chart 4.0 (AD Instruments, Grand Junction, CO) on a Power Mac G4 computer (Apple, Cupertino, CA).For each subject two minutes of baseline FBF were recorded and then the upper arm cuff was inflated to 200 mmHg pressure for five minutes to occlude flow to the arm. It was then released and forearm blood flow was measured for the next minute.
- Glucose [ Time Frame: 3 months ]Plasma glucose
- Insulin [ Time Frame: 3 months ]Plasma insulin
- HOMA [ Time Frame: 3 months ]Insulin resistance
- Triglycerides [ Time Frame: 3 months ]Plasma Triglycerides
- LDL [ Time Frame: 3 months ]LDL level
- HDL [ Time Frame: 3 months ]Plasma HDL
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00373386
|United States, Ohio|
|Ohio State University|
|Columbus, Ohio, United States, 43210|
|Study Chair:||Robert P Hoffman, MD||Ohio State University|